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ABSTRACT 
Objective: To develop and validate a high-performance liquid chromatographic method (HPLC) for the determination of nifedipine (NFD) 
concentration in rat plasma. 
Methods: 1.5 mol of sodium hydroxide solution was added to each plasma sample, followed by the addition of an extraction solvent based on n-
hexane and dichloromethane (70: 30, v/v). The organic layer was transferred and evaporated to dryness under nitrogen flow. The residue was 
reconstituted with 0.5 mol of acetic acid, followed by the addition of n-hexane. After centrifuging the mixture, the supernatant organic layer of n-
hexane was discarded, and the aqueous solution was injected onto the HPLC using A Phenomenex Luna-C18 reversed phase analytical column (250 
x 4.6 mm, 5 µm). The mobile phase consisted of 0.01 mol aqueous ammonium formate: methanol: acetonitrile (55: 43: 2, v/v) with pH adjusted to 
4.9 using formic acid. The flow rate was 0.8 ml/min; UV detector set at 235 nm and the samples were quantified using the peak area. 
Results: A well-resolved NFD peak was achieved free of interference from endogenous compounds in rat plasma. Recovery of NFD was more than 
93 % over concentrations ranged from 5.00 to 200 ng/ml. The limit of quantification (LOQ) of this assay was 6 ng/ml and, intra-and inter-day 
coefficient of variation (CV) were 5.75 % and 7.93 %, respectively. NFD was found to be stable in rat plasma after being stored at -30 °C over 90 d.  
Conclusion: The stability, sensitivity, specificity and reproducibility of this method make it suitable for the determination of NFD plasma 
concentration in pharmacokinetics and oral bioavailability studies. 
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pyridine dicarboxylic acid dimethyl ester [1], is a dihydropyridine 
calcium channel blocker commonly used in the treatment of 
hypertension, angina pectoris and atherosclerosis [2]. The empirical 
formula for NFD is C17H18N2O6 and its molecular weight is 346.33 
g/mol [fig. 1]. In the market, NFD is available in the form of retard or 
prolonged-release (Adalat®) tablets containing 20 or 60 mg of NFD, 
respectively. According to the Biopharmaceutical Classification 
System
Several analytical methods have been published for the 
determination of NFD in biological samples. They were based on gas 
chromatography (GC) with different detectors [16-20], HPLC with 
UV detection [21-26], voltammetric method [8], electrochemical 
detection and LC-MS [27-28]. However, some of these methods were 
not completely validated and applying peak height quantification 
rather than peak area quantification. Furthermore, they required 
long running times for drug detection using large amounts of blood 
samples (up to 1 ml). Besides, most of these sensitive HPLC methods 
reported so far were using tandem mass spectrometry [29-30]. 
Some of these NFD CG analytical methods using a split–splitless 
injector port might cause thermal degradation of NFD as mentioned 
earlier, lead to oxidation of the dihydropyridine moiety of NFD, and 
result in formation of the NFD metabolites (dehydronifepinine) by 
oxidative dehydrogenation [16]. 
 (BCS), NFD is a class II drug, poorly soluble in water (<10 
mg/l) [3], but rapidly absorbed from the GIT due to its lipophilic 
nature [4]. However, NFD has very low plasma concentration related 
to the presystemic metabolism resulting in a very low oral 
bioavailability (up to 70 %) [5] and inter/intra individual 
pharmacokinetic variations [6, 7]. Following absorption, NFD is 
further metabolized via the major hepatic metabolizing enzyme 
(CYP3A4) into inactive polar metabolites [8]. The elimination half-life 
is approximately 2-5 h [9, 10]. On the other hand, a 96 % degradation 
of NFD in methanol solution has been reported upon it's exposure to 
normal light for 2 h [11]. Besides, a decomposition of NFD upon 
injection to the injection port has been reported as a result of thermal 
instability [12–15]. The low profile of plasma concentration of NFD 
based on low oral bioavailability, photo-degradation due to light 
sensitivity and thermal instability during analysis requires a very 
sensitive, simple and practical method of analysis.  
In this paper, the use of HPLC-UV was highlighted as an alternative 
method for GC analysis to avoid the possibility of thermal degradation 
by controlling the temperature of the injector port and column during 
NFD separation. Thus, a sensitive, selective, reproducible and stabile 
HPLC-UV assay of NFD concentration in rat plasma was developed and 
validated for accuracy, precision, recovery, linearity and long-term 
stability. This simple method was verified by analyzing plasma 
samples from rats after oral administration of NFD solution. Only the 
collection of a few blood samples (100 µl) was required. The 
concentration was quantified by peak area. 
MATERIALS AND METHODS 
Materials 
Chemicals (suppliers) were as follows: NFD and diazepam (Sigma 
Aldrich Co., St. Louis, USA); Pharmaceutical grade of poly-(ethylene 
glycol) 400 (PEG) (Merck KGaA, Darmstadt, Germany); HPLC grade 
formic acid and ammonium formate (Fluka, Darmstadt; Germany); 
HPLC grade n-hexane, dichloromethane, sodium hydroxide, 
acetonitrile and methanol (Merck, Darmstadt; Germany); Glacial 
acetic acid (BDH Laboratory Supplies Poole, England).  
Methods 
HPLC system for plasma samples 
The analytical instrument used was a Shimadzu HPLC system 
(Shimadzu Corporation, Japan) consisting of an LC-10A vp 
Intelligent HPLC pump and an SPD-10A vp detector set 235 nm and 
a Rheodyne 7725i injector fitted with a 50 µl sample loop. A 
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Phenomenex Luna-C18 reversed phase analytical column (250 x 4.6 
mm, 5 µm) fitted with a Refillable Phenomenex guard column (10 x 
2 mm, 5 µm) was used. The mobile phase (MP) was a mixture of 0.01 
mol aqueous ammonium formate: methanol: acetonitrile (55: 43: 2, 
v/v) adjusted to pH 4.9 using formic acid. The flow rate of MP was 
running at 0.8 ml/min and the column temperature was set at 37 °C. 
Data were collected and processed using Shimadzu Class VP version 
7.4 software and samples were quantified using the peak area. 
Pharmacokinetic study design  
NFD preparation (1 mg/ml) for oral administration was prepared by 
dissolving a 50 mg aliquot of NFD in 50 ml of PEG 400 (co-solvent) 
and mili-Q water (1:1, v/v) and stirred thoroughly at room 
temperature for 1 h. The drug solution was protected from light at 
preparation time and stored immediately after in the fridge to be 
used within 12 h of preparation. NFD was administered to the rats 
orally by gavage in the dose of 5 mg/kg. Five male Wister rats (age 
2-3 mo, weight 290±30 g) were used in the experiment. They were 
kept in the experimental animal facility and given standard diet and 
water ad libitum. Temperature and light were controlled mimicking 
the natural habitat. The study was approved by Animal Ethics 
Committee. Blood samples were collected into heparinized tubes 
from the tip of the tail pre-dose and at 15, 30, 60, 90, 120, 150, 180, 
240, 300 and 360 min after the dose. Blood samples were 
centrifuged at 3,000 rpm for 15 min to collect the plasma, which was 
stored at-30 °C prior to HPLC analysis. Immediately after the last 
blood sample, rats were sacrificed by carbon dioxide asphyxiation. 
Samples were analyzed within 6 d of collections. 
Sample preparation 
Prior to analysis, NFD was extracted from plasma samples as follow: 
80 µl of plasma aliquot was transferred into a micro-eppendorf tube 
followed by the addition of 15 µl of internal standard (15 µg/ml of 
diazepam) and 20 µl of 1.5 mol sodium hydroxide solution. The 
mixture was vortex-mixed for 30 s and 400 µl of n-hexane: 
dichloromethane (70: 30, v/v) was added as an extraction solvent. 
The resultant organic layer was transferred into another glass tube 
and evaporated to dryness at 40 °C under nitrogen gas. The dry 
residue was reconstituted with 200 µl of 0.5 mol acetic acid 
followed, by the addition of 800 µl hexane. The mixture was again 
vortex-mixed for 30 s and centrifuged at 5.000 rpm for 10 min. The 
n-hexane layer was completely discarded and only 100 µl of the 
aqueous solution was injected into the HPLC system. 
Assay validation  
Based on a number of previous reported methods [21-26, 31-33], 
The HPLC assay validation method was developed as following: A 
stock solution of an aliquot NFD (25 µg/ml) was prepared by 
dissolving 2.5 mg aliquot of NFD in 100 ml of a mixture containing 
mili-Q water and methanol (20: 80, v/v) and then NFD (25 µg/ml) 
was further diluted to 250 ml with mili-Q water and methanol to 
obtain a 100 ng/ml of NFD calibration curve solution. Three 
different batches of six standard curves each were prepared by 
spiking rat plasma with NFD calibration curve solution, spiking MP 
with NFD calibration curve solution and spiking PEG with NFD 
calibration curve solution to give concentrations in the range over 5 
to 100 ng/ml. QC samples (6, 12, 24 and 48 ng/ml of NFD) were 
prepared by spiking blank rat plasma with NFD calibration curve 
solution. The calibration curve solutions were stored at-30 °C until 
used for assay validation and sample analysis. Linearity was 
assessed by least–square regression and lack-of-fit analysis. 
Accuracy was expressed as the percentage of the spiked 
concentration and precision as the coefficient of variation (CV). LOQ 
is defined as the concentration with signal-to-noise ratios of 10: 1. 
For inter-day, accuracy and precision determination analyses of 
each concentration were carried out daily for 6 consecutive days 
whereas for intra-day accuracy and precision evaluations analyses 
were carried out 6 times on the same day. Recovery was estimated 
by comparing peak areas in QC samples (n = 6) with drug solutions 
at corresponding concentrations. The stability of NFD was tested in 
plasma at 4 different concentrations (12.5, 25, 50 and 100 ng/ml 
NFD). Short term stability at -30 °C was tested for freshly prepared 
samples and over 2 d, while long term stability was tested at-30 °C 
over 30 and 90 d. Another stability test was carried on after 5 
freeze-thawing cycles for each sample at-30 and 25 °C. 
Statistical analysis 
Analysis of variance (one-way ANOVA) was used to compare mean 
values of variables determined for different calibration curves 
spiked with different materials. Differences were considered 
statistically significant when *p<0.05. The analysis was performed 
using the Minitab program (Version 15; Minitab Inc, USA). 
RESULTS 
The NFD peak with a retention time of 4.8 min was well-resolved 
and free from the interference of endogenous compounds in rat 
plasma. The total run time for each sample was 6 min. At least six 
calibration curve standards of rat plasma were tested. Thus, blank 
plasma was used in the preparation of the calibration curves. NFD 
was found to be stable in plasma after being protected from light for 
at least 24 h at room temperature with no noticeable changes in NFD 
concentrations in plasma. 
The calibration curve of NFD spiked with rat plasma, PEG and MP (n 
= 6) reported in table 1 were linear over the concentration range 
from 5.00 to 100 ng/ml (r2 0.9997±0.0016) with a mean intercept of 
0.0132±0.0509. Similarly, the calibration curve of NFD spiked with 
PEG and MP (table 1) was linear over the same concentration range 
(r2
For verification, this developed method was used to analyze plasma 
samples from five rats after an oral administration of 5 mg/kg NFD 
solution. Fig. 2 shows the plasma concentration-time profiles for 
NFD over 6 h after the oral dose (5 mg/kg) of NFD solution. It is 
apparent that the presented HPLC method is sensitive enough to 
detect the plasma concentration-time profiles for a drug with well-
known low oral bioavailability. 
 0.9998±0.0023 and 0.9996±0.0064) with a mean intercept of-
0.0904±0.0281 and+0.0176±0.0371, respectively. It is evident that a 
linear correlation is existed between the peak area and the 
concentrations of NFD spiked with rat plasma, PEG and MP. This 
result also demonstrates that no considerable interference exists as 
no significant difference was found (p>0.05). 
Measured NFD, inter-and intra-day accuracy and precision values 
for different NFD concentrations are presented in table 2 and table 
3, respectively. The lowest concentration was used in the 
construction of QC samples was 6 ng/ml at which intra-and inter-
day CV were 5.75 % and 7.93 % with a recovery of more than 93 %. 
This verifies that the present method is very sensitive. Furthermore, 
the present experimental setup was testing the NFD stability in 
plasma before extraction. NFD was found to be stable in rat plasma 
after 5 freeze-thawing cycles for each sample at-30 and 25 °C and 
after storage at -30 °C over 90 d (table 4). These results proof that 
the assay is stable, selective and sufficiently sensitive for oral 
bioavailability and pharmacokinetic studies in rats. 
.  
Table 1: Comparison between r2
St Curves 
, slopes and intercepts of different standards curves (NFD–HPLC assay) 
Regression (r2 Slope (mean±SD) ) Intercept (mean±SD) 
Plasma spiked with NFD 0.9997±0.0016 1.0029±0.32 +0.0132±0.0509 
PEG spiked with NFD 0.9998±0.0023 1.0371±0.14 -0.0904±0.0281 
MP spiked with NFD 0.9996±0.0064 1.0083±0.52 +0.0176±0.0371 
Data are means±SD, n=6. 
Table 2: Measured NFD, Intra-day accuracy and precision of the HPLC method for the analysis of NFD in rat plasma samples 
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Nominal [NFD] (ng/ml) Measured [NFD] (ng/ml) Accuracy (%) Precision (CV) (%) 
6.00 5.05±0.30 93.40±1.01 5.75±0.52 






47.6±2.11 96.17±0.98 2.17±0.48 
Data are means±SD, n=6. 
 
Table 3: Measured NFD, Inter-day accuracy and precision of the HPLC method for the analysis of NFD in rat plasma samples 
Nominal [NFD] (ng/ml) Measured [NFD] (ng/ml) Accuracy (%) Precision (CV) (%) 
6.00 5.15±0.02 93.73±0.56 7.93±0.28 






47.3±0.60 98.17±0.56 4.18±0.85 
Data are means±SD, n=6. 
 




at 1 h  
(ng/ml) 
[NFD] 
at 2 d  
(ng/ml) 
[NFD ] 
at 30 d  
(ng/ml) 
[NFD] 
at 90 d  
(ng/ml) 
[NFD] 
at 5 freeze-thawing cycles 
(ng/ml) 
12.5 12.4±0.25 12.4±0.25 11.4±0.16 11.3±0.53 11.5±1.03 
25.0 24.8±0.21 24.8±0.51 24.6±0.74 24.5±0.86 24.0±0.68 
50.0 49.6±0.52 49.6±0.52 49.5±0.85 49.4±0.92 48.9±1.26 
100 99.8±1.31 99.8±1.31 99.5±1.08 99.3±1.95 98.4±3.81 
Data are means±SD, n=6 
 
 
Fig. 1: Chemical structure of nifedipine (NFD) 
 
 
Fig. 2: Plasma concentration-time profile of NFD after oral 




A number of analytical methods have been reported for 
determination of NFD in plasma [16-28]. The HPLC method 
developed here is based on a number of previously reported 
methods [21-26, 31-33], but with modifications to the organic 
modifier ratios and concentrations in the MP, the flow rate, the pH 
strength and the volume of the extraction agent. The ratio of organic 
solvent in the MP is essential to retain the drug molecule on the 
stationary phase of the column. Thus, the assessment of MP 
containing buffer solution with different pH strength in combination 
with several organic solvents such as acetonitrile, methanol and 
triethylamine with different volume were tested.  
To determine an optimal amount of organic solvent, which can be 
used in the MP for the separation of the analyte, 35 to 65 % of the 
organic solvent mixture (methanol and acetonitrile) was used. The 
best peak separation with short analysis time was obtained, when 
the percentage of the organic solvent mixture (methanol and 
acetonitrile) in the MP was 45 %. The addition of 43% methanol and 
2% acetontrile were found to be necessary to produce a well-
resolved peak, free of interference from adjacent endogenous 
compounds.  
The effect of different pH strength and buffer concentration in MP on 
NFD retention time and resolution were assessed. Several 
concentrations of the aqueous ammonium formate in the buffer 
solution varying from 0.01 to 0.05 mol were tested. As a result of 
this assessment, no significant change in retention and resolution of 
NFD was observed, when the concentration of buffer has increased 
from 0.01 to 0.05 mol. For pH assessment, previous studies showed 
that NFD exhibits maximum stability in solutions with low pH value, 
as NFD is a weak acid drug molecule having low pKa value of 3.93 
[34]. Therefore, different pH values with acidic range as mentioned 
earlier were assessed for NFD peak resolution and retention. The 
retention of NFD was significantly unchanged in the buffered 
solution over the tested pH ranges (3.5 to 6.5) with clear peak 
resolution appearance. However, a mobile phase with pH 4.9 was 
chosen to protect the used column from the low pH effect on column 
validity. As a result of this MP assessment, a good NFD retention 
with less than 6 min running time for analysis was obtained.  
For normal light protection, a complete NFD degradation has been 
reported upon exposure to normal light for 2 h [11]. Based on these 
findings, an appropriate protection from light during sample 
preparation was taken into account to avoid any possibility of drug 
photo-degradation for the plasma sample during treatments. A 
number of organic solvents have been reported for NFD extraction, 
Arafat et al. 
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such as dichloromethane [35], diethyl ether [13], a mixture of 
hexane and dichloromethane [36], a mixture of isooctane and 
methyl-tert-butyl ether [37], ethyl acetate [38], a mixture of n-
pentane and dichloromethane [39] and chloroform [40]. Based on 
that, many organic solvent mixtures with different ratios were 
assessed such as a mixture of diethyl ether and ethyl acetate, a 
mixture of isooctane and methyl-tert-butyl ether and a mixture of n-
hexane with dichloromethane. The result from this assessment study 
showed that less cloudy samples with an optimum recovery (up to 70 
%) for NFD could be obtained by using a mixture of n-hexane and 
dichloromethane (70: 30, v/v). Therefore, the addition of 20 µl of 1.5 
mol sodium hydroxide solution prior to the addition of organic solvent 
mixture was necessary for complete extraction to eliminate any 
sample turbidity and to increase the recovery of NFD up to satisfactory 
level. Thus, the used extraction solvents were found to be essential to 
give satisfactory recoveries for NFD and to provide distinctive 
chromatograms. Besides, a linear correlation existed between the peak 
area ratio of plasma, MP and PEG spiked NFD. Under the experimental 
conditions used, LOQ of this assay was found to be 6 ng/ml, whereas 
LOD was found to be 2 ng/ml. This points out that the present method 
was found to be very sensitive stable.  
It is evident that the plasma concentration of NFD after the oral 
administered dose was low indicating low oral bioavailability of NFD 
when administered orally. However, the presently developed 
method is highly sensitive to detect the plasma concentration-time 
profiles for a drug with well-known low oral bioavailability (0.47-
0.82%) [41]. HPLC method developed in this paper is applicable for 
the determination of NFD in vivo studies of different kind of NFD 
drug delivery dosage forms [42]. 
CONCLUSION  
In conclusion, the HPLC method described here is simple, sensitive, 
selective, reproducible, linear, precise, accurate with short retention 
time and stable requiring only a small blood collection volume from 
rat plasma. The method was fully validated and is applicable for the 
determination of NFD in vivo as well as for the assessment of 
pharmacokinetic and oral bioavailability studies of the different type 
of drug dosage forms. 
CONFLICT OF INTERESTS 
Declared none  
REFERENCES 
1. Stone PH, Antman EM, Muller JE, Braunwald E. Calcium channel 
blocking agents in the treatment of cardiovascular disorders. 
Part II: hemodynamic effects and clinical applications. Ann 
Intern Med 1980;93:886-904. 
2. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of 
its pharmacodynamic and pharmacokinetic properties and 
therapeutic efficacy, in ischaemic heart disease, hypertension 
and related cardiovascular disorders. Drugs 1985;30:182–
274. 
3. Cao QR, Cui JH, Park JB, Han HK, Lee J, Oh KT, Park I, Lee BJ. Effect of 
food components and dosing times on the oral pharmacokinetics of 
nifedipine in rats. Int J Pharm 2010;396:39-44. 
4. Abrahamsson B, Alpsten M, Bake B, Jonsson UE, Eriksson-
Lepkowska M, Larsson A. Drug absorption from nifedipine 
hydrophilic matrix extended release (ER) tablet-comparison 
with an osmotic pump tablet and effect of food. 
J Controlled Release 1998;52:301-10. 
5. Filgueira GC, Filgueira OA, Carvalho DM, Marques MP, Moisés 
EC, Duarte G, et al. Analysis of nifedipine in human plasma and 
amniotic fluid by liquid chromatography-tandem mass 
spectrometry and its application to clinical pharmacokinetics 
6. Raemsch KD, Sommer J. Pharmacokinetics and metabolism of 
nifedipine. Hypertension 1983;5:18–24. 
in 
hypertensive pregnant women. J Chromatogr B: Anal Technol 
Biomed Life Sci 2015;993-994:20-5. 
7. Eichelbaum M, Echizen H. Clinical pharmacology of calcium 
antagonists: a critical review. J Cardiovasc Pharmacol 
1984;6:S963-7. 
8. Ozaltin N, Yardimci C, Suslu I. Determination of nifedipine in 
human plasma by square wave adsorptive stripping 
voltammetry. J Pharm Biomed Anal 2002;30:573-82. 
9. Guengerich FB, Martin MV, Beaune PH, Kremers P, Wolff T, 
Waxman DJ. Characterization of rat and human liver 
microsomal cytochrome P-450 forms involved in nifedipine 
oxidation, a prototype for genetic polymorphism in oxidative 
drug metabolism. J Biol Chem 1986;261:5051–60.  
10. Challenor VF, Waller DG, Renwick AG, Gruchy BS, George CF. 
The trans-hepatic extraction of nifedipine. Br J Clin Pharmacol 
1987;24:473-7.  
11. Rosseel MT, Bogaert MG. Determination of nifedipine in human 
plasma by capillary gas chromatography with nitrogen 
detection. J Chromatogr 1983;279:675-80.  
12. Abou-Auda HS, Najjar TA, Al-Hadiya KI, Ghilzai NM, Al-Fawzan 
NF. Liquid chromatographic assay of nifedipine in human 
plasma and its application to pharmacokinetic studies. J Pharm 
Biomed Anal 2000;22:241-9.  
13. Goldnik A, Gajewska M, Marszałek D, 
14. Jankowski A, Lamparczyk H. Evaluation of chromatographic 
methods for the determination of nifedipine in human serum. J 
Chromatogr A 1994;668:469-73. 
Przyzyçki M. 
Determination of nifedipine in serum by HPLC. Acta Pol Pharm 
1996;53:7-8.  
15. Grundy JS, Kherani R, Foster RT. Sensitive high-performance 
liquid chromatographic assay for nifedipine in human plasma 
utilizing ultraviolet detection. J Chromatogr B: Biomed Appl
16. Schmid BJ, Perry HE, Idle JR. Determination of nifedipine and 
its three principal metabolites in plasma and urine by 
automated electron-capture capillary gas chromatography. J 
Chromatogr 1988;425:107-19.  
 
1994;654:146-51. 
17. Patrick KS, Jarvi EJ, Straughn AB, Meyer MC. Gas 
chromatographic mass spectrometric analysis of plasma 
nifedipine. J Chromatogr 1989;495:123-30.  
18. Le Guellec C, Bun H, Giocanti M, Durand A. Determination of 
nifedipine in plasma by a rapid capillary gas chromatographic 
method. Biomed Chromatogr 1992;6:20-3. 
19. Horváth V, Hrabéczy-Páll A, Niegreisz Z, Kocsi E, Horvai G, 
Gödörházy L, et al. Sensitive high-performance liquid 
chromatographic determination of nifedipine in dog plasma 
using an automated sample preparation system with laboratory 
robot. J Chromatogr B: Biomed Appl 1996;686:211-9.  
20. Streel B, Zimmer C, Sibenaler R, Ceccato A. Simultaneous 
determination of nifedipine and dehydronifedipine in human 
plasma by liquid chromatography-tandem mass spectrometry. 
J Chromatogr B; Biomed Sci Appl 1998;720:119-28.  
21. Kostewlcz E, Sansom L, Flshlock R, Morella A, Kuchel T. 
Examination of two sustained release nifedipine preparations 
in humans and in pigs. Eur J Pharm Sci 1996;4:351-7. 
22. Yritia M, Parra P, Iglesias E, Barbanoj JM. Quantitation of 
nifedipine in human plasma by on-line solid-phase extraction 
and high-performance liquid chromatography. J Chromatogr A 
2000;870:115-9. 
23. Zhiping L, Mingkang Z, Xiaojin S, Zhongdong L. 
24. Niopas I, Daftsios AC. Determination of nifedipine in human 
plasma by solid phase extraction and high-performance liquid 
chromatography: validation and application to pharmacokinetic 
studies. J Pharm Biomed Anal 2003;32:1213-8. 
A solid phase 
extracted-HPLC method for determining nifedipine in human 
plasma. J Clin Pharm 2005;14:115-7.  
25. Vertzoni MV, Reppas C, Archontaki HA. Sensitive and simple 
liquid chromatographic method with ultraviolet detection for 
the determination of nifedipine in canine plasma. Anal Chim 
Acta 2006;573-574:298-304. 
26. Zendelovska D, Simeska S, Sabinovska O, Kostova E, Milosevska K, 
Jakovski K, et al. Development of an HPLC method for the 
determination of nifedipine in human plasma by solid-phase 
extraction. J Chromatogr B: Anal Technol Biomed Life Sci 
2006;839:85-8. 
27. Guo Y, Dai J, Qian G, Guo N, Ma Z, Guo X. Determination of 
nifedipine in human plasma and its use in bioequivalence 
study. Int J Pharm 2007;341:91-6. 
Arafat et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 8, 98-102 
102 
28. Wang XD, Li JL, Lu Y, Chen X, Huang M, Chowbay B, et al. Rapid 
and simultaneous determination of nifedipine and 
dehydronifedipine in human plasma by liquid 
chromatography-tandem mass spectrometry: Application to a 
clinical herb-drug interaction study. J Chromatogr B: Anal 
Technol Biomed Life Sci 2007;852:534-44.  
29. Dankers J, van den Elshout J, Ahr G, Brendel E, van der Heiden 
C. Analytical determination of nifedipine in human plasma by 
flow-injection tandem mass spectrometry. J Chromatogr B: 
Biomed Sci Appl 
30. Baranda AB, Mueller CA, Alonso RM, Jimenez RM, Weinmann 
W. Quantitative determination of the calcium channel 
antagonists amlodipine, lercanidipine, nitrendipine, felodipine, 
and lacidipine in human plasma using liquid chromatography-
tandem mass spectrometry. Ther Drug Monit 2005;27:44-52. 
1998;710:115-20. 
31. Golocorbin-Kon S, Mikov M, Arafat M, Lepojevic Z, Mikov I, 
Sahman-Zaimovic M. Cefotaxime pharmacokinetics after oral 
application in the form of 3alpha,7alphadihydroxy-12-keto-
5beta-cholanate microvesicles in rat. Eur J Drug Metab 
Pharmacokinet 2009;34:31-6. 
32. Arafat M, Golocorbin Kon S, Mikov M. The measurement of 
cefotaxime sodium in rat plasma after oral administration: a 
sensitive HPLC-UV method. Int J Pharm Pharm Sci 2015;7:343-6. 
33. Arafat M. Simple HPLC validated method for determination of 
diltiazem hydrochloride in human. Int J Pharm Pharm 
Sci 2014;6:213-6. 
34. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson 
EJ, Berkland C. Nifedipine nanoparticle agglomeration as a dry 
powder aerosol formulation strategy. Int J Pharm 
2009;369:136-43. 
35. Zaater M, Hasan E, Najib N. Trace-level determination of 
nifedipine in human serum by reversed phase high 
performance liquid chromatography. Pol J Pharmacol 
2000;52:307-12. 
36. Jankowski A, Lamparczyk H. Evaluation of chromatographic 
methods for the determination of nifedipine in human serum. J 
Chromatogr A 1994;668:469-73. 
37. Grundy JS, Kherani R, Foster RT. Sensitive high-performance 
liquid chromatographic assay for nifedipine in human plasma 
utilizing ultraviolet detection. J Chromatogr B: Biomed 
Appl 
38. Thongnopnua P, Viwatwongsa K. Quantitative analysis of 
nifedipine in plasma by high-performance liquid 
chromatography. J Pharm Biomed Anal 1994;12:119-25. 
1994;654:146-51.  
39. Soons PA, Schellens JH, Roosemalen MC, Breimer DD. Analysis 
of nifedipine and its pyridine metabolite dehydronifedipine in 
blood and plasma: review and improved high-performance 
liquid chromatographic methodology. J Pharm Biomed Anal 
1991;9:475-84.  
40. Gurley BJ, Buice RG, Sidhu P. Reversed-phase high performance 
liquid chromatographic determination of nifedipine in human 
plasma. Ther Drug Monit 1985;7:321-3. 
41. Rashid TJ, Martin U, Clarke H,  Waller DG,  Renwick AG,  George 
CF. Factors affecting the absolute bioavailability of nifedipine. 
Br J Clin Pharmacol 1995;40:51-8. 
42. Arafat M. Approaches to achieve an oral controlled release drug 
delivery system using polymers: a recent review. Int J Pharm 
Pharm Sci 2015;7:16-21. 
How to cite this article 
• Mosab Arafat, Zahaa Ahmed, Momir Mikov. Determination of 
nifedipine in rat plasma using hplc-uv detector: a simple 
method for pharmacokinetics and oral bioavailability studies. 
Int J Pharm Pharm Sci 2016;8(8):98-102. 
 
